http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Won Tae,Yun, Seok Joong,Yan, Chunri,Jeong, Pildu,Kim, Ye Hwan,Lee, Il-Seok,Kang, Ho-Won,Park, Sunghyouk,Moon, Sung-Kwon,Choi, Yung-Hyun,Choi, Young Deuk,Kim, Isaac Yi,Kim, Jayoung,Kim, Wun-Jae Yonsei University College of Medicine 2016 Yonsei medical journal Vol.57 No.4
<P><B>Purpose</B></P><P>Our previous high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry study identified bladder cancer (BCA)-specific urine metabolites, including carnitine, acylcarnitines, and melatonin. The objective of the current study was to determine which metabolic pathways are perturbed in BCA, based on our previously identified urinary metabolome.</P><P><B>Materials and Methods</B></P><P>A total of 135 primary BCA samples and 26 control tissue samples from healthy volunteers were analyzed. The association between specific urinary metabolites and their related encoding genes was analyzed.</P><P><B>Results</B></P><P>Significant alterations in the carnitine-acylcarnitine and tryptophan metabolic pathways were detected in urine specimens from BCA patients compared to those of healthy controls. The expression of eight genes involved in the carnitine-acylcarnitine metabolic pathway (<I>CPT1A, CPT1B, CPT1C, CPT2, SLC25A20</I>, and <I>CRAT</I>) or tryptophan metabolism (<I>TPH1</I> and <I>IDO1</I>) was assessed by RT-PCR in our BCA cohort (n=135). C<I>PT1B, CPT1C, SLC25A20, CRAT, TPH1</I>, and <I>IOD1</I> were significantly downregulated in tumor tissues compared to normal bladder tissues (<I>p</I><0.05 all) of patients with non-muscle invasive BCA, whereas <I>CPT1B, CPT1C, CRAT</I>, and <I>TPH1</I> were downregulated in those with muscle invasive BCA (<I>p</I><0.05), with no changes in <I>IDO1</I> expression.</P><P><B>Conclusion</B></P><P>Alterations in the expression of genes associated with the carnitine-acylcarnitine and tryptophan metabolic pathways, which were the most perturbed pathways in BCA, were determined.</P>
Isaac Yi Kim,황은아,Chinedu Mmeje,Matthew Ercolani,이동현 연세대학교의과대학 2010 Yonsei medical journal Vol.51 No.3
Purpose: The objective of this study is to evaluate the continence rate following reconstruction of the posterior urethral plate in robot-assisted laparoscopic radical prostatectomy (RLRP). Materials and Methods: A retrospective analysis of 50 men with clinically localized prostate cancer who underwent RLRP was carried out. Twenty-five patients underwent RLRP using the reconstruction of the posterior aspect of the rhabdosphincter (Rocco repair). Results of 25 consecutive patients who underwent RLRP prior to the implementation of the Rocco repair were used as the control. Continence was assessed at 7, 30, 90, and 180 days following foley catheter removal using the EPIC questionnaire as well as a follow-up interview with the surgeon. Results: There was no statistically significant difference between the two groups in any of the patient demographics. At 7 days, the Rocco experimental group had a continence rate of 19% vs. 38.1% in the non-Rocco control group (p = 0.306). At 30days, the continence rate in the Rocco group was 76.2% vs. 71.4% in the non-Rocco group (p = 1). At 90 days, the values were 88% vs. 80% (p = 0.718), respectively. At 180 days, the pad-free rate was 96% in both groups. Conclusion: Rocco repair offers no significant advantage in the time to recovery of continence following RLRP when continence is defined as the use of zero pads per day. On the other hand, Rocco repair was associated with increased incidence of urinary retention requiring prolonged foley catheter placement.
Transforming Growth Factor-β : Biology and Clinical Relevance
Kim, Isaac Yi,Kim, Moses M.,Kim, Seong-Jin 한국생화학분자생물학회 (구 한국생화학회) 2005 BMB Reports Vol.38 No.1
Transforming growth factor-β is a pleiotropic growth factor that has enthralled many investigators for approximately two decades. In addition to many reports that have clarified the basic mechanism of transforming growth factor-β signal transduction, numerous laboratories have published on the clinical implication/application of transforming growth factor-β To name a few, dysregulation of transforming growth factor-β signaling plays a role in carcinogenesis, autoimmunity, angiogenesis, and wound healing. In this report, we will review these clinical implications of transforming growth factor-β.
Kim, Won Tae,Yun, Seok Joong,Choi, Young Deuk,Kim, Gi-Young,Moon, Sung-Kwon,Choi, Yung Hyun,Kim, Isaac Yi,Kim, Wun-Jae The Korean Academy of Medical Sciences 2011 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.26 No.9
<P>We evaluated the correlations between BMI, fasting glucose, insulin, testosterone level, insulin resistance, and prostate size in non-diabetic benign prostatic hyperplasia (BPH) patients with normal testosterone levels. Data from 212 non-diabetic BPH patients with normal testosterone levels, who underwent transurethral resection of the prostate (TURP) due to medical treatment failure, were evaluated retrospectively. Patients with prostate specific antigen (PSA) levels of ≥ 3 ng/mL underwent multicore transrectal prostate biopsy before TURP to rule out prostate cancer. Patients with diabetes mellitus (DM) or serum testosterone levels of < 3.50 ng/mL were excluded from analysis. Correlations between clinical and laboratory parameters were determined. Prostate size correlated positively with age (<I>r</I> = 0.227, <I>P</I> < 0.001), PSA (<I>r</I> = 0.510, <I>P</I> < 0.001), and fasting glucose level (<I>r</I> = 0.186, <I>P</I> = 0.007), but not with BMI, testosterone, insulin level, or insulin resistance (each P > 0.05). Testosterone level inversely correlated with BMI (<I>r</I> = -0.327, <I>P</I> < 0.001), insulin level (<I>r</I> = -0.207, <I>P</I> = 0.003), and insulin resistance (<I>r</I> = -0.221, <I>P</I> = 0.001), but not with age, prostate size, PSA, or fasting glucose level (each <I>P</I> > 0.05). Upon multiple adjusted linear regression analysis, prostate size correlated with elevated PSA (<I>P</I> < 0.001) and increased fasting glucose levels (<I>P</I> = 0.023). In non-DM BPH patients with normal testosterone levels, fasting glucose level is an independent risk factor for prostate hyperplasia.</P>
Shim, Ui Jae,Lee, Il-Seok,Kang, Ho Won,Kim, Jayoung,Kim, Won Tae,Kim, Isaac Yi,Ryu, Keun Ho,Choi, Yung Hyun,Moon, Sung-Kwon,Kim, Yong-June,Yun, Seok-Joong,Lee, Sang-Cheol,Kim, Wun-Jae The Korean Urological Association 2013 Korean Journal of Urology Vol.54 No.9
<P><B>Purpose</B></P><P>The deleted in bladder cancer 1 (<I>DBC1</I>) gene is located within chromosome 9 (9q32-33), a chromosomal region that frequently shows loss of heterozygosity in bladder cancer (BC). It is suspected that it acts as a tumor suppressor gene, but its prognostic value remains unclear. The aim of the present study was to investigate the value of <I>DBC1</I> as a prognostic marker in BC.</P><P><B>Materials and Methods</B></P><P>The expression of <I>DBC1</I> was determined by real-time polymerase chain reaction analysis in 344 patients with BC (220 non-muscle-invasive BC [NMIBC] and 124 muscle-invasive BC [MIBC]) and in 34 patients with normal bladder mucosa. The results were compared with clinicopathologic parameters, and the prognostic value of <I>DBC1</I> was evaluated by Kaplan-Meier analysis and a multivariate Cox regression model.</P><P><B>Results</B></P><P><I>DBC1</I> expression was significantly decreased in patients with MIBC compared with those diagnosed with NMIBC (p=0.010). Patients with aggressive tumor characteristics had lower <I>DBC1</I> expression levels in NMIBC (each, p<0.05). By multivariate Cox regression analysis, low <I>DBC1</I> expression was a predictor of progression to MIBC (hazard ratio, 7.104; p=0.013). Kaplan-Meier estimates revealed a significant difference in tumor recurrence, progression to MIBC, and cancer-specific survival depending on the level of <I>DBC1</I> expression in NMIBC (log-rank test, each, p<0.05).</P><P><B>Conclusions</B></P><P>The expression of <I>DBC1</I> was associated with tumor aggressiveness, progression to MIBC, and survival in NMIBC. Our results suggest that <I>DBC1</I> expression can be a useful prognostic marker for patients with NMIBC.</P>
Downregulation of Fumarate Hydratase Is Related to Tumorigenesis in Sporadic Renal Cell Cancer
Ha, Yun-Sok,Chihara, Yoshitomo,Yoon, Hyung-Yoon,Kim, Yong-June,Kim, Tae-Hwan,Woo, Seung Hyo,Yun, Seok-Joong,Kim, Isaac Yi,Hirao, Yoshihiko,Kim, Wun-Jae S. Karger AG 2013 Urologia internationalis Vol.90 No.2
<P>Abstract</P><P><B><I>Objective:</I></B> Although germline mutations of fumarate hydratase<B> </B>(FH) are a useful molecular marker of hereditary leiomyomatosis and renal cell cancer (RCC) syndrome, their clinical significance in sporadic RCC has not been studied in detail. The aim of the present study was to investigate possible correlations between the expression of <I>FH</I> and the clinical implications of sporadic RCC. <B><I>Materials and Methods:</I></B><I>FH</I> mRNA levels were evaluated in 140 tumor specimens from patients with primary RCC and in 62 specimens of corresponding normal-appearing kidney tissue using real-time quantitative polymerase chain reaction. Immunohistochemical staining was performed on 6 normal surrounding tissues and 71 RCC tissues. <B><I>Results:</I></B><I>FH</I> mRNA levels were significantly lower in tumor tissues than in matched normal-appearing kidney tissues (p = 0.031). In all normal tissues, FH staining intensity was strong. However, the expression of <I>FH</I> showed no significant correlation with the pathological and clinical characteristics of patients with sporadic RCC. <B><I>Conclusions:</I></B> Our results showed that <I>FH</I> mRNA expression decreased significantly in correlation with the transition from normal renal parenchyma to RCC. <I>FH</I> may be an indicator or tumorigenesis in sporadic RCC and could be a potential target for therapies against RCC in the future.</P><P>Copyright © 2012 S. Karger AG, Basel</P>